Oxford Finance LLC
Venture debtAlexandria · Growth · 42 people tracked
Find your way into Oxford Finance LLC
Sign up to see every warm intro you have to Oxford Finance LLC
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Oxford Finance LLC team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Oxford Finance's real estate and asset-based lending team focuses on the acute, post-acute, and specialty healthcare segments, financing owners and operators of properties such as skilled nursing, assisted living, memory care, and hospitals. It provides capital for working capital, acquisitions, refinancing, cash-out recapitalizations, and property transitions, lending against single assets or portfolios that are operator- or investor-owned and located in the United States. Products include working capital revolvers, senior term loans, term loan B and second lien facilities, mezzanine loans, equity and structured equity, and full capital markets capabilities, with facility sizes from $5M to $125M, tenors up to five years, initial interest-only periods, and amortization of up to 25 years.
Source: firm website, verified Sep 29, 2026.
Team · 42 people
from the firm's website & public directoriesWhat they invest in
from 10 of 10 portfolio companiesBiotech ×7Healthtech ×2AI & Machine Learning ×1Creator Economy ×1E-commerce ×1EdTech ×1Media & Entertainment ×1Medical Devices ×1
HQs:United States×8Canada×1
Investments · 10 tracked
founders shown can be your intro pathBy year:2021 · 12020 · 12012 · 24 dated
Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset.
BiotechEmeryville, US
Warner Biddle(Chief Executive Officer)inBrian Kotzin(Director)Ian Clark(Director)Ryan Jones(Executive Officer)Karen Walker(Executive Officer)Peter Maag(Executive Officer, Director)in
Co-investorsBain Capital Life SciencesVida VenturesWestlake Village BioPartnersGilead SciencesInsight PartnersKleiner Perkins+3 more
Narvii.com is an independent information website that publishes articles about digital platforms, online communities, and popular apps.
Creator EconomyMedia & EntertainmentSocial
Alexander Smith(Editor-in-Chief)
Co-investorsBantam GroupHighland Capital PartnersTRANSFORMATION CAPITAL
Amino Labs produces hands-on biotechnology experiment kits designed to teach genetic engineering and bacterial transformation to beginners in educational and hobbyist settings.
BiotechEdTechSouthern Alberta, CA
Julie Legault(CEO)inJustin Pahara(Biotechnology Expert)
Co-investorsSOSVThe E14 FundAccelAspect VenturesCRV (Charles River Ventures)Highland Capital Partners+1 more
Fynd provides a commerce platform with AI agents for sales and support, letting brands build websites, sell on marketplaces (Amazon, Myntra, Noon, Trendyol), run wholesale operations, modernise retail stores, and manage orders, payments, and logistics.
AI & Machine LearningE-commerceRetail TechSaaSSeattle, US
Farooq Adam(Founder)inSreeraman Mohan Girija(Founder)inNicolas Nezhat(President)
Co-investorsFJ LabsgrowX VenturesKae CapitalRajul Sandeep JhaveriRocketship.vcTitan Capital+7 more
Inhibrx develops protein therapeutics, using target biology and protein engineering to create therapeutic candidates in clinical trials for conditions including sarcoma and head and neck cancer.
BiotechLa Jolla, US
Mark Lappe(Executive Officer, Director)inBrendan Eckelman(Director)inDoug Forsyth(Director)Jon Faiz Kayyem(Director)Margery Fischbein(Director)
BoardJudith Li(Director)
Co-investorsLAVLilly Asia VenturesRA CapitalViking Global
BiotechBridgewater, US
Navneet Puri(Executive Officer)
Co-investorsH.I.G. CapitalH.I.G. HealthBridge Partners
A biopharmaceutical company that discovers, develops, and delivers medicines and vaccines, with research and development across respiratory, immunology and inflammation, oncology, HIV, and infectious diseases.
BiotechHealthtechMedical DevicesSan Francisco, US
Co-investorsCapital Midwest FundFrazier Life SciencesLongitude CapitalRA CapitalVivo Capital
Tarsa Therapeutics developed TBRIA, an oral formulation of calcitonin for treating postmenopausal osteoporosis in women more than five years post menopause when other treatments are unsuitable.
BiotechPhiladelphia, US
David Brand(Executive Officer, Director)inGregory Lumpkin(Executive Officer)
BoardRichard Kollender(Director)Martin Edwards(Director)Eric Bednarski(Director)Derek Ferguson(Director)
Co-investorsForesite CapitalMVM Life Science PartnersQuaker BioVentures
Exits · 2
1 IPOs · 1 acquisitions · showing 1Kyverna TherapeuticsNASDAQ: KYTX
Portfolio news
latest coverage across their companies
Kyverna Therapeutics · biospace.com · Sep 3, 2026
Frequently asked questions
- How many investments has Oxford Finance LLC made?
- Oxford Finance LLC has 10 tracked investments, 2 of which have exited.
- What stage does Oxford Finance LLC invest at?
- Oxford Finance LLC invests at the Growth stage.
- What sectors does Oxford Finance LLC focus on?
- Oxford Finance LLC focuses on Biotech, Healthtech, Medical Devices, PropTech.
- Where is Oxford Finance LLC located?
- Oxford Finance LLC is headquartered in Alexandria, US.
- Does Oxford Finance LLC lead rounds?
- Yes, Oxford Finance LLC leads investment rounds.
Similar investors
Innovestor is a Finnish investment manager active in venture capital, real estate, and energy storage, and also provides corporate venturing services.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Norwest is a venture capital and growth equity investment firm that has backed over 700 companies across technology, consumer, and healthcare over its 65-year history.
Summit Partners is a growth equity investment firm that partners with management teams across technology, healthcare & life sciences, and growth products & services sectors to build long-term value.
K3 Ventures presents itself as an investment platform focused on collaboration and partnership between founders and stakeholders, emphasizing trust, relevance, and long-term support.




































































